46 results about "Right ventricles" patented technology

An implantable lead for use with an implantable medical device (IMD) includes a tubular lead body having a proximal portion including a proximal end, a distal portion including a distal end opposite the proximal end, and an intermediate portion between the proximal portion and the distal portion. A helical electrode extends distally from the distal end of the tubular lead body. At least one atrial electrode is disposed in the intermediate portion of the tubular lead body. At least one electrical conductor extends through the tubular lead body and is mechanically and electrically coupled to the helical electrode and the at least one atrial electrode. The intermediate portion may have a pre-formed bend configured to urge the at least one atrial electrode against a surface of the right atrium when the lead is implanted. A distal pre-formed bend located in the distal portion of the tubular lead body may be configured to bias a plurality of pacing / sensing electrodes towards a surface of a right ventricle. A distal pre-formed bend located in the distal portion of the tubular lead body may be configured to bias the helical electrode and at least one pacing / sensing against a surface of a right ventricle.

A system for monitoring right ventricular systolic dysfunction includes a hemodynamic sensor that produces a hemodynamic sensor signal representative of a right ventricular pressure waveform of the patient, a display, one or more processors, and computer-readable memory. The computer-readable memory is encoded with instructions that, when executed by the one or more processors, cause the system to receive the hemodynamic sensor signal representative of the right ventricular pressure waveform of the patient, extract right ventricular peak systolic pressure and right ventricular end diastolic pressure from the right ventricular pressure waveform of the patient, determine a ratio of right ventricular peak systolic pressure over right ventricular end diastolic pressure, and output the ratio of right ventricular peak systolic pressure over right ventricular end diastolic pressure to the display for monitoring the presence of right ventricular systolic dysfunction based on the ratio of peak systolic pressure over end diastolic pressure.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

A system for determining a global hypoperfusion index (GHI) includes an arterial blood pressure sensor, a ventricular blood pressure sensor, an oximetry module, and an integrated hardware unit including a system processor and a system memory. The system memory includes instructions that cause the system to receive arterial hemodynamic data, ventricular hemodynamic data, and blood oxygen saturation data. One or more right ventricular pressure features, one or more pulmonary artery pressure features, one or more cardiac output parameters, and one or more venous oxygen saturation parameters are derived from the arterial hemodynamic data, the ventricular hemodynamic data, and the blood oxygen saturation data. The GHI is derived by using a predictive decision model based upon the one or more right ventricular pressure features, the one or more pulmonary artery features, the one or more cardiac output parameters, and the one or more venous oxygen saturation parameters.

Methods and systems are provided for a rate adaptive bi-ventricular fusion pacing. The methods and systems deliver a first pulse at a left ventricular (LV) lead and a second pulse at a right ventricular (RV) lead based on a paced atrio-ventricular (AV) delay. The first pulse timed to be delivered concurrently with an intrinsic ventricular conduction. The methods and systems further repeat the delivery of the first pulse and the second pulse for a predetermined number of cycles. Additionally, the methods and systems measure an intrinsic AV conduction interval, and adjust the paced AV delay based on the intrinsic AV conduction interval and a negative hysteresis delta.

An ultrasound imaging and backscatter system includes an ICE ultrasound catheter having an ultrasound pMUT transducer array disposed within a distal end of the ultrasound catheter and including a plurality of transducer array elements disposed on a substrate. One end of the catheter shaft is connected to the handle assembly and the other end is connected to the ultrasonic transducer array. The catheter shaft accommodates an electronic flexible cable in communication with the signal trace and directs each of the plurality of transducer array elements to transmit and receive an ultrasound beam, receives at least one signal from the plurality of transducer array elements, and constructs at least one image characterizing one or more tissue components of the scanned object. An ultrasound imaging system is used to measure tissue thickness, tissue scar, and lesion assessment for left atrium, right atrium, left ventricle, and right ventricle tissue wall characteristics and other intracardiac tissue anomalies.

A system for improving the function of a defective heart includes a tubular membrane, a replacement valve, a set of one or more inlets, and a set of one or more outlets. The tubular membrane encompasses (i) a first chamber of the system, shaped to conform to an interior region of a right atrium of the heart, and (ii) a second chamber of the system, shaped to conform to an interior region of a right ventricle of the heart. The replacement valve is configured to separate the first chamber from the second chamber, and has leaflets for providing flow in only one direction. The one or more inlets connect the first chamber with a first portion of cardiovascular anatomy, and the one or more outlets connect the second chamber with a second portion of cardiovascular anatomy.

A system for monitoring right ventricular systolic dysfunction includes a hemodynamic sensor that generates a hemodynamic sensor signal representative of a right ventricular pressure waveform of a patient, a display, one or more processors, and a computer readable memory. The computer-readable memory is encoded with instructions that, when executed by the one or more processors, cause the system to receive a hemodynamic sensor signal representative of a right ventricular pressure waveform of the patient, extract a right ventricular peak systolic pressure and a right ventricular end diastolic pressure from the right ventricular pressure waveform of the patient, and transmit the extracted right ventricular peak systolic pressure and right ventricular end diastolic pressure to the one or more processors. A ratio of the right ventricular peak systolic pressure to the right ventricular end diastolic pressure is determined, and the ratio of the right ventricular peak systolic pressure to the right ventricular end diastolic pressure is output to a display to monitor the presence of the right ventricular systolic dysfunction based on the ratio of the peak systolic pressure to the end diastolic pressure.

The embodiment of the application provides a right ventricular assist system and a control method of a right ventricular assist device. The right ventricular assist device comprises a blood-out cage, a blood-in cage, a pumping assembly and a driving assembly. The driving assembly, the pumping assembly and the blood-in cage are located in the inferior vena cava, and the blood-out cage is located in the pulmonary artery. The driving assembly drives the pumping assembly to rotate in the clockwise direction, pushes the blood from the blood-in cage into the blood-out cage, and then into the pulmonary artery. The target motor in the driving assembly is a brushless hollow cup motor, which is composed of a rotor and a stator. The angle between the magnetic induction lines of the rotor magnetic field and the stator magnetic field is a fixed angle, which is an angle between 40 degrees and 50 degrees. The controller comprises a level determination module, a current determination module, a current mapping module, a current fusion module, a voltage determination module and a motor control module. By using the embodiment, the control of the right ventricular assist device can be adapted to the real-time change state of the heart.

The application provides a blood supply and demand balance adjustment method and system of a total artificial heart and the total artificial heart, and belongs to the technical field of medical devices. The blood supply and demand balance adjustment method of the total artificial heart obtains the real-time blood supply and demand balance index of the total artificial heart, compares the blood supply and demand balance index with the blood supply and demand balance index threshold obtained and set in advance, and obtains the blood supply information of the total artificial heart to the human body. In the case that the blood supply information of the total artificial heart to the human body shows that the blood supply of the left ventricle of the total artificial heart and the right ventricle of the total artificial heart to the human body is unbalanced, the running speed of one of the left and right ventricles is changed based on the correlation between the running speed of the power system and the blood pumping capacity of the ventricle, and the blood pumping capacity of the left and right ventricles is also changed, so that the blood supply of the left and right ventricles can be accurately adjusted in real time to achieve balance.

The utility model discloses a transcatheter pulmonary valve replacement simulation simulator, which comprises a liquid storage tank, a liquid outlet, a liquid inlet, a liquid outlet and a liquid outlet, the side wall of the liquid storage tank is provided with a mounting port, the mounting port is provided with a cable gland, and the cable gland is used for penetrating through a surgical instrument and realizing dynamic sealing with the surgical instrument; the model assembly is arranged in the liquid storage tank, the model assembly is used for simulating the cardiovascular structure of a human body, and the model assembly comprises a pulmonary artery simulation tube, a heart simulation body and a lower cavity approach tube which are connected in sequence; wherein the heart simulation body is provided with a right atrium, a right ventricle and a tricuspid valve simulation body located between the right atrium and the right ventricle, the pulmonary artery simulation tube is communicated with the right ventricle, a first end of the inferior lumen approach tube is communicated with the right atrium, a second end of the inferior lumen approach tube is communicated with the right ventricle, and a third end of the inferior lumen approach tube is communicated with the right ventricle. The second end of the lower cavity inlet pipe corresponds to the cable gland in position.

The application discloses a use of taibai araloside in treating hypoxic pulmonary arterial hypertension. In the use of hypoxia to induce pulmonary arterial hypertension, it is found that the taibai araloside can reduce right ventricular pressure and right heart hypertrophy index, and inhibit pulmonary arterial remodeling; the taibai araloside reduces the expression and activity of ACE in the lung in a concentration-dependent manner, and corrects the disorder of the RAS system in the lung caused by hypoxic pulmonary arterial hypertension. Moreover, a monomer component of the taibai araloside, anemarrhena asphodeloides glycoside and chizhenshan saponin IVa, has a stable combination with ACE. The results show that the taibai araloside has the potential to be developed into a drug for preventing and treating hypoxic pulmonary arterial hypertension in the clinic, and also provides a prevention and treatment strategy for interstitial lung disease, chronic obstructive pulmonary disease, sleep apnea syndrome, chronic high altitude disease and neonatal respiratory disease.

The invention provides a traditional Chinese medicine composition for treating pulmonary arterial hypertension and application thereof, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition for treating pulmonary arterial hypertension is prepared from the following components in parts by weight: 5-7 parts of herba ephedrae, 7-9 parts of semen armeniacae amarae, 20-24 parts of gypsum, 5-7 parts of liquorice root, 9-11 parts of radix salviae miltiorrhizae, 0.8-1.2 parts of leech and 2.5-3.5 parts of radix notoginseng. According to the treatment principle of freeing lung, relieving asthma and promoting blood circulation to remove blood stasis, ephedra, apricot kernel, gypsum and licorice granules with the effects of freeing lung, clearing heat and relieving asthma are used as monarch drugs, and salvia miltiorrhiza, leech and pseudo-ginseng with the effects of promoting blood circulation to remove blood stasis are used as ministerial drugs for compatibility; the prepared traditional Chinese medicine composition can reduce the length ratio of the right ventricle to the left ventricle plus ventricular septum and the length ratio of the right ventricle to the tibia, inhibit right ventricular hypertrophy, repair pulmonary vascular injury and improve the pulmonary ventilation function, the cardio-pulmonary function and pulmonary arterial hypertension.

The invention relates to a cardiac assist system comprising: - an intraventricularly implantable cardiac pump, - a processing unit, - at least one lead intended to be placed on an external wall of the heart. The processing unit includes a cardiac pump management function, a pacing function, and / or a defibrillation function. The processing unit is configured to: - perform cardiographic impedance measurements between said at least one lead and a metallic part of the cardiac pump in order to determine the following hemodynamic parameters: - a cardiac electromechanical delay from the cardiographic impedance measurements, - a blood filling time in the heart from the cardiographic impedance measurements, - a blood ejection time from the heart from the cardiographic impedance measurements, and - a change in right ventricular and / or left ventricular volume over time.Figure for the abridged version: Fig. 1.

The present disclosure includes devices and techniques for threading one or more catheters to the apex or base of the right ventricle by transfemoral vein access to the right ventricle. The catheter can be passed through to turn upward, directed towards the mitral valve, by puncturing the ventricular septum into the left ventricle through the ventricular side or right side of the heart. From this entry point in the left ventricle, flail mitral valve leaflets can be sutured and tethered, pulled back into place, and re-attached with grounding anchors in the right ventricle, or embedded in the septal wall. The ventricular septal crossing technique may include passing a coaxial conduit through a first access conduit, where the first access conduit may act as a guide to direct an inner or second coaxial conduit toward a flail mitral valve leaflet.

This application proposes a method and apparatus for controlling the rotation speed of a ventricular assist device (VAD). The method includes: acquiring a first left ventricular pressure and a first right ventricular pressure, wherein the first left ventricular pressure is the left ventricular pressure of the target user at a first moment when the left ventricular assist device is running at a first left rotation speed, and the first right ventricular pressure is the right ventricular pressure of the target user at a first right rotation speed when the right ventricular assist device is running at a first right rotation speed; adjusting the first left rotation speed and / or the first right rotation speed according to the first left ventricular pressure and the first right ventricular pressure to maintain a balance between the fluid output of the left and right ventricles. This application determines whether the fluid output of the user's left and right ventricles is balanced by real-time detection of ventricular pressure, and then adjusts the rotation speed of the left ventricular assist device and / or the right ventricular assist device to regulate the fluid output of the left or right ventricle when there is an imbalance, thereby ensuring a balance between the systemic and pulmonary circulation flow of the user and preventing aspiration and regurgitation problems in the left or right ventricle.

The present invention relates to an implantable medical device (1) for stimulating a human or animal heart. During operation, the implantable medical device (1) executes a method comprising the following steps: a) detecting a right ventricular electric signal, the detected right ventricular electric signal comprising a plurality of right ventricular events (13); b) calculating a mean right ventricular interval (15) from a predeterminable number of at least some right ventricular events (13) of the plurality of right ventricular events (13); c) detecting a left ventricular electric signal with the second electrode (9), the detected left ventricular electric signal comprising a plurality of left ventricular events (16); d) calculating a mean left ventricular interval (18) from a predeterminable number of at least some left ventricular events (16) of the plurality of left ventricular events (16); e) if at least one of the mean right ventricular interval (15) and the mean left ventricular interval (18) falls below a value lying in the range of from 200 ms to 2000 ms, determining a deviation between the mean right ventricular interval (15) and the mean left ventricular interval (18); f) if the deviation between the mean right ventricular interval (15) and the mean left ventricular interval (18) is bigger than a threshold, triggering a storing of at least a part of the detected right ventricular electric signal and / or of at least a part of the detected left ventricular electric signal in the memory unit (33) to allow a later evaluation of the stored part of the right ventricular electric signal and / or of the left ventricular electric signal.

The utility model relates to the technical field of medical teaching, and discloses a human body model used for anesthesia ultrasonic teaching, which comprises a simulated human body, a chest simulation module, a bionic pump, a liquid storage device and an arm simulation module, and is characterized in that the chest simulation module comprises a simulated heart, a simulated head and arm trunk and a simulated superior vena cava; the left atrium of the simulated heart is communicated with the output end of the bionic pump, the right ventricle of the simulated heart and the input end of the bionic pump are communicated with the liquid storage device, the arm simulation module comprises a first pipeline and a second pipeline, and the left ventricle of the simulated heart is communicated with the front end of the first pipeline and the front end of the second pipeline through a simulated head-arm shaft. And the rear end of the first pipeline and the rear end of the second pipeline are respectively communicated with the right atrium of the simulated heart through the simulated superior vena cava. A plurality of simulation modules are arranged in the simulation human body, the comprehensiveness is high, the blood circulation of the human body can be simulated, and the simulation degree is high.

The utility model relates to the field of hemodynamic simulation, and discloses a cardiovascular hemodynamic simulation device. According to the application, a right atrium, a left atrium, a left ventricle and a right ventricle are sequentially arranged in the simulated heart main body, simulated walls are arranged among the right atrium, the left atrium, the left ventricle and the right ventricle, air bags are arranged in the right atrium, the left atrium, the left ventricle and the right ventricle, and pressing plates are arranged at the top ends of the right atrium, the left atrium, the left ventricle and the right ventricle; through the arrangement of the right atrium, the left atrium, the left ventricle and the right ventricle, the specific functions of each heart structure and the role of each heart structure in blood circulation are helped to be understood, meanwhile, students and medical workers can better master the physiological mechanism and related pathological states of the heart, the overall cognition of the cardiovascular system is improved, and the development of the cardiovascular system is promoted. The matched simulation wall can effectively separate the right atrium, the left atrium, the left ventricle and the right ventricle, and the arrangement of the pressing plate and the air bag facilitates heartbeat simulation of the structure.

The application provides use of a trisaccharide compound with a core structure of GlcN(1→4)IdoA(1→4)GlcNS in preparation of a drug for treating or preventing pulmonary arterial hypertension, which can effectively improve right ventricular hypertrophy, right ventricular function damage and hemodynamic parameters of an animal model of the pulmonary arterial hypertension, delay or improve excessive proliferation of arterial endothelial cells and smooth muscle cells in the pulmonary arterial hypertension, treat vascular remodeling and vascular muscularization of a pulmonary arterial hypertension patient, and has a good protective effect on a heart in the pulmonary arterial hypertension.

The present disclosure relates to a right ventricle segmentation method, a heart-lung analysis method and device, an electronic device and a storage medium, and relates to the technical field of right ventricle analysis. The right ventricle segmentation method comprises: acquiring a chest image to be segmented, a first preset segmentation model and a second preset segmentation model; using the first preset segmentation model to perform overall segmentation of a left ventricle and a right ventricle on the chest image to be segmented to obtain a first segmentation image; using the second preset segmentation model to perform left ventricle segmentation on the chest image to be segmented to obtain a second segmentation image; and determining a right ventricle image based on the first segmentation image and the second segmentation image. The embodiment of the present disclosure can realize accurate segmentation of the right ventricle in the chest image, and further realize heart-lung analysis.

This application relates to a positioning balloon and a blood pump system. The positioning balloon includes a balloon, a positioning tube, and a guide tube. The balloon can be implanted into the right ventricle and has an inflation cavity, allowing it to inflate. The balloon bends in an arc shape when inflated. The guide tube is connected to the balloon and at least partially passes through the inflation cavity of the balloon, allowing for the insertion of a pre-embedded guidewire. The positioning tube is located within the inflation cavity of the balloon and bends with the balloon during inflation. The positioning tube has a proximal opening and a distal opening exposed on the outside of the balloon, allowing the flexible main body of the pump to be inserted into the positioning tube. The blood inlet of the pump is located outside the proximal opening, and the blood outlet is located outside the distal opening. The positioning balloon of this application can position the blood pump in the right ventricle, allowing the distal end of the blood pump to extend directly towards the pulmonary artery after passing through the positioning balloon, avoiding the blood pump from impacting the internal tissues of the right ventricle and reducing the difficulty of blood pump implantation.

A use of a trisaccharide compound having a core structure of GlcN(1→4)IdoA(1→4)GlcNS in the preparation of a drug for treating or preventing pulmonary hypertension. The drug can effectively alleviate right ventricular hypertrophy and right ventricular dysfunction and optimize hemodynamic parameters in an animal model of pulmonary hypertension, slow down or ameliorate excessive proliferation of arterial endothelial cells and smooth muscle cells in pulmonary hypertension, treat vascular remodeling and vascular muscularization in patients with pulmonary hypertension, and has a good protective effect on a heart in pulmonary hypertension.

A method for providing therapeutic treatment to reduce pre-load may be provided. The method may include placing a ventricular assist device (VAD) at least partially within a left ventricle or a right ventricle of a patient, and placing a catheter-based device including an adjustable flow limiting element (FRE) such that the FRE is disposed within a superior vena cava (SVC) of the patient. The method may include receiving information from the VAD and / or conduit-based FRE device, determining a first determination value based on the information, and controlling at least one performance parameter of the VAD and / or conduit-based device based on the first determination value.

This invention relates to the field of cardiac electrophysiological diagnostic technology, and discloses a method and system for extracting pulmonary hypertension features based on magnetocardiography. The method includes: acquiring the cardiac magnetic field strength distribution matrix of the subject and calculating the magnetic field gradient direction vector; extracting the zero-position feature trajectory of the magnetic field gradient direction vector to determine the respiratory displacement compensation value and correct the spatial coordinates of the magnetic field distribution; analyzing the distribution symmetry of the magnetic field gradient direction vector to establish a rotation axis reference; calculating the angular displacement offset of the magnetic field gradient direction vector relative to the rotation axis reference and generating gradient rotation feature parameters; determining the angular distribution consistency index of the magnetic field gradient direction vector and establishing the phase-locked characteristic time, and calibrating the gradient rotation feature parameters. This invention, by constructing a geometric reference for the topological evolution of the magnetic field, eliminates the influence of anatomical position deviations of the subject, captures the rotational distortion of the right ventricular electrical conduction path, and improves the accuracy of pathological feature extraction.

The present technology generally includes devices, systems, and methods for providing electrical stimulation to the left ventricle of a human heart in a patient suffering from Left Bundle Branch Block (LBBB). In particular, the present technology includes an implantable receiver-stimulator and an implantable controller-transmitter for leadless electrical stimulation of the heart. The receiver-stimulator can include one or more sensors capable of detecting the electrical conduction of the heart and the receiver-stimulator can be configured to pace the stimulation of the left ventricle based off the sensed electrical conduction to achieve synchronization of the left and right ventricles.

A right ventricular assist device (RVAD) (420) is provided that includes a pulsatile- flow pump (424) defining a pump chamber (426) that includes first and second sub- chambers (427A, 427B) in fluid isolation from each other. Proximal and distal cannulas (438, 432) are configured to be inserted into a right ventricle (450) and couplable to an artery (302) of the systemic circulation, respectively, and arranged in fluid communication with a proximal opening (428) of the first sub-chamber (427A) and a distal opening (430) of the second sub-chamber (427B), respectively. The pulsatile-flow pump (424) provides pulsatile flow synchronized with the cardiac cycle in a counterpulsation mode by, during at least a portion of ventricular diastole, pumping blood in a distal direction out of the distal opening (430) and drawing blood in the distal direction into the proximal opening (428); and during at least a portion of ventricular systole, pumping blood in the opposite direction. Other embodiments are also described.